thalidomide has been researched along with Schnitzler Syndrome in 2 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Schnitzler Syndrome: An extremely rare condition manifested as monoclonal IMMUNOGLOBULIN M dysproteinemia without features of lymphoproliferative disease, but with chronic urticaria, fever of unknown origin, disabling bone pain, hyperostosis, and increased erythrocyte sedimentation rate.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Worm, M | 1 |
| Kolde, G | 1 |
| de Koning, HD | 1 |
| Bodar, EJ | 1 |
| Simon, A | 1 |
| van der Hilst, JC | 1 |
| Netea, MG | 1 |
| van der Meer, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Canakinumab in Schnitzler Syndrome[NCT01276522] | Phase 2 | 8 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for thalidomide and Schnitzler Syndrome
| Article | Year |
|---|---|
Schnitzler's syndrome: successful treatment of two patients using thalidomide.
Topics: Humans; Immunosuppressive Agents; Interleukin-6; Schnitzler Syndrome; Thalidomide; Treatment Outcome | 2003 |
Beneficial response to anakinra and thalidomide in Schnitzler's syndrome.
Topics: Antirheumatic Agents; Female; Follow-Up Studies; Humans; Interleukin 1 Receptor Antagonist Protein; | 2006 |